Key result
Newer generation TKIs linked to ~29% incidence of vascular adverse events in CML.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2015) conducted an editorial in Chronic myeloid leukemia (CML). Newer generation tyrosine kinase inhibitors (nilotinib, ponatinib) was evaluated. Newer generation tyrosine kinase inhibitors, such as nilotinib and ponatinib, are associated with a high incidence of vascular adverse events (up to 29.4%) in patients with chronic myeloid leukemia.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: